Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Stress Levels Periodontitis and Metabolic Syndrome

11 novembre 2026 mis à jour par: Dilek KARADOĞAN, Recep Tayyip Erdogan University Training and Research Hospital

Evaluation of Salivary Cortisol, Dehydroepiandrosterone, Chromogranin A, and Psychological Stress Levels in Patients With Periodontitis and Metabolic Syndrome

The purpose of this observational study is to evaluate the levels of salivary cortisol, dehydroepiandrosterone, and chromogranin A, as well as the levels of psychological stress, in patients with periodontitis and/or metabolic syndrome. The primary research question the study aims to address is:

- Are the levels of salivary cortisol, dehydroepiandrosterone, and chromogranin A and psychological stress in patients with periodontitis and/or metabolic syndrome associated with their periodontal status and metabolic syndrome?

Participants-categorized into a control group, those with periodontitis only, those with metabolic syndrome only, and those with both periodontitis and metabolic syndrome-will undergo a clinical periodontal examination, provide saliva samples for the assessment of cortisol, dehydroepiandrosterone, and chromogranin A levels, and complete validated scales designed to measure psychological stress. The findings will help clarify the relationship between psychological stress, stress-related salivary biomarkers, metabolic syndrome, and periodontal health.

Aperçu de l'étude

Statut

Pas encore de recrutement

Description détaillée

Within the scope of the study, the Rosenberg Self-Esteem Scale and the Social Appearance Anxiety Scale will be administered. Salivary markers-cortisol, dehydroepiandrosterone, and chromogranin A-will be analyzed using the ELISA method. Periodontal clinical parameters (plaque index, gingival index, bleeding on probing, probing pocket depth, and clinical attachment loss) will be measured.

Type d'étude

Observationnel

Inscription (Estimé)

100

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Rize Province
      • Rize, Rize Province, Turquie (Türkiye), 53020
        • Department of Periodontology of the Faculty of Dentistry of Recep Tayyip Erdogan University
        • Contact:
          • RTEU Faculty of Dentistry, Department of Periodontology
          • Numéro de téléphone: +90 464 222 00 00
          • E-mail: dis@erdogan.edu.tr

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Individuals who presented to the Internal Medicine Outpatient Clinic at the Recep Tayyip Erdoğan University Faculty of Medicine Training and Research Hospital and met the diagnostic criteria for metabolic syndrome as defined by the American Diabetes Association (ADA) or the International Diabetes Federation (IDF); healthy volunteers who presented to the Periodontology Clinic at the Recep Tayyip Erdoğan University Faculty of Dentistry; and individuals who were diagnosed with periodontitis but did not meet the criteria for metabolic syndrome.

La description

Inclusion Criteria:

  • Individuals between the ages of 18 and 65,
  • Those who have at least 20 natural teeth,
  • Individuals who have provided written informed consent for participation in the research
  • Individuals diagnosed with periodontitis and/or metabolic syndrome

Exclusion Criteria:

  • Individuals who have received periodontal treatment (surgical or non-surgical) within the last 6 months,
  • Individuals with a history of using antibiotics, anti-inflammatory drugs, or immunosuppressive medications within the last 3 months,
  • Individuals with a history of systemic disease who do not meet the criteria for metabolic syndrome (e.g., malignancy, autoimmune diseases, liver/kidney failure),
  • Individuals who have been diagnosed with a psychiatric disorder or are undergoing regular psychiatric treatment,
  • Pregnant or breastfeeding women,
  • Individuals with physical or mental disabilities that prevent them from maintaining their oral hygiene.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: CASE_CONTROL
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Healthy Control Group

Individuals with no clinical or radiographic signs of periodontal disease and no history of systemic disease

Periodontitis Group (Systemically Healthy)

Individuals diagnosed with periodontitis according to the 2018 American Academy of Periodontology classification, but with no history of systemic disease

Metabolic Syndrome Group (Periodontally Healthy)

Individuals diagnosed with metabolic syndrome according to American Diabetes Association or International Diabetes Federation criteria, but without periodontitis

Periodontitis + Metabolic Syndrome Group

Individuals diagnosed with both metabolic syndrome and periodontitis

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Plaque Index
Délai: Day 1

Plaque Index (PI) (Silness and Löe, 1964) This index is used to evaluate the amount of dental plaque accumulation on tooth surfaces. Each tooth's four surfaces (buccal, lingual, mesial, distal) are examined using a probe or visually. Each surface is scored from 0 to 3. The average score is calculated for each tooth. The overall plaque index is obtained by averaging the scores from all examined teeth.

Score Description

0 No plaque.

  1. No visible plaque, but a slight film of plaque is detected when a probe is run along the gingival margin.
  2. Visible plaque along the gingival margin, forming a continuous band.
  3. Abundant plaque covering the gingival area and extending toward the middle of the tooth surface, including the interproximal spaces.
Day 1
Gingival Index
Délai: Day 1

The Gingival Index is used to assess the presence and severity of gingival inflammation (gingivitis). Four surfaces of each tooth (buccal, lingual, mesial, distal) are examined visually and with a periodontal probe. The evaluation considers color changes, edema (swelling), tissue consistency, and bleeding on probing. Each surface is scored from 0 to 3. The average score per tooth is calculated, and then the overall average is used to determine the individual's GI score.

Score Description

0 Healthy gingiva: normal color and texture, no bleeding

  1. Mild inflammation: slight color change and swelling, no bleeding on probing
  2. Moderate inflammation: redness, edema, soft tissue, bleeding on probing
  3. Severe inflammation: marked redness and swelling, ulceration, possible spontaneous bleeding
Day 1
Bleeding on Probing Index
Délai: Day 1

This index is used to assess the presence and severity of gingival inflammation by observing bleeding after gentle pressure is applied to the gingival sulcus using a periodontal probe. A thin periodontal probe is gently inserted into the gingival sulcus with light pressure (approximately 20-25 grams). Bleeding occurring within 10-30 seconds is observed. Each measurement site is recorded as either "bleeding present" or "bleeding absent." Presence of bleeding is an early and sensitive indicator of gingival inflammation.

Score Description: 0 No bleeding 1 Bleeding present (mild or severe)

Day 1
Probing Pocket Depth
Délai: Day 1

Using a Williams periodontal probe, the distance between the gingival margin and the base of the periodontal pocket is measured in millimeters at six sites per tooth: mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual. All teeth are measured. The values obtained from each site are summed and then divided by the total number of sites measured. This gives the average probing depth for the individual.

Measurement Interpretation

1-3 mm Healthy sulcus

4-5 mm Shallow to moderate pocket

≥6 mm Deep periodontal pocket (advanced disease)

Day 1
Clinical Attachment Loss
Délai: Day 1

Using a Williams periodontal probe, the distance between the enamel-cementum junction and the base of the periodontal pocket is measured in millimeters at six sites per tooth: mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual. All teeth are measured. The values obtained from each site are summed and then divided by the total number of sites measured. This gives the average probing depth for the individual.

Clinical Attachment Loss Value Interpretation

0-1 mm Healthy / minimal loss

2-3 mm Mild attachment loss

4-5 mm Moderate attachment loss

≥6 mm Severe attachment loss

Day 1
Collection of Saliva Samples
Délai: Day 2

Prior to saliva collection, participants will be instructed to abstain from caffeine and/or nicotine for at least 4 hours and alcohol for at least 24 hours. Saliva will be collected between 9:00 AM and 11:00 AM to minimize circadian variations. Unstimulated saliva flow rate will be collected over 10 minutes using the spitting method and will be expressed in mL/min.

Day 2

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Rosenberg Self-Esteem Scale Score
Délai: Day 1

A four-point scale will be used to score responses to the 10 items. Positive questions are scored as 3: Strongly agree; 2: Agree; 1: Disagree; and 0: Strongly disagree, while negative questions are scored as 0: Strongly agree; 1: Agree; 2: Disagree; and 3: Strongly disagree. According to the final total score of the Rosenberg Self-Esteem Scale scores between 0-15, 15-25, and 25-30 indicate low, normal, and high self-esteem levels, respectively.

Day 1
Social Appearance Anxiety Scale Score
Délai: Day 1

Social Appearance Anxiety Scale 16-item scale concerns how patients feel about their appearance. A score of 1 to 5 is given for each item as follows: 1, completely disagree; 2, partially disagree; 3, unsure; 4, partially agree; 5, I completely agree. Scores range from 16 to 80, with higher scores representing greater social appearance anxiety.

Day 1
Concentration of Cortisol, Dehydroepiandrosterone and Chromogranin A
Délai: approximately in the 4th month

Salivary cortisol, Dehydroepiandrosterone and Chromogranin A will be obtained from unstimulated whole saliva samples. Saliva samples will be stored at -20°C until analyzed. Human salivary cortisol, Dehydroepiandrosterone, and Chromogranin A will be measured using radioenzyme immunoassay using a commercial enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions.

approximately in the 4th month

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

16 novembre 2026

Achèvement primaire (Estimé)

15 mars 2027

Achèvement de l'étude (Estimé)

19 avril 2027

Dates d'inscription aux études

Première soumission

11 novembre 2026

Première soumission répondant aux critères de contrôle qualité

11 novembre 2026

Première publication (Réel)

17 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner